



ALPHAPHARM

PHARMACEUTICALS

RECEIVED

21 JAN 1998

Dir.
Eval.

SB:3049/sjb

19 January 1998

Director
Drug Safety and Evaluation Branch
Therapeutic Goods Administration
P O Box 100
Woden ACT 2606

Dear Sir/Madam,

**Re: Product information and marketing date for
isosorbide mononitrate 60 mg sustained release tablets ("Duride")**
File no. 96/31307, AN 97/016/3

Reference is made to your letter dated 15 October 1997 approving our application for registration of the above product. Alphapharm wishes to advise that we will begin marketing **Duride** on 1 February 1998, and that this product will also be listed as a pharmaceutical benefit item on that date.

Enclosed are two copies of the approved product information, annotated with a statement that it has been approved by the Therapeutic Goods Administration on the date of the approval letter.

Yours sincerely,
Alphapharm Pty Limited

Anne

S. Bennett
Sonia J. Bennett B.Sc.(Hons)
Senior Regulatory Affairs Associate

Encl:

COMPUTER UPDATED

Date: 6-2-98

App. No. 97.016.3

WTAD: AS

Original
copy

Adm 96/31308
Cler 96/31307

* Please wait - Ring company on 2nd February '98 & confirm that supp. date was as stated above.

* Then action as per SOP's

* Update date for both < supply date
PI.

* Action PI as per SOP's

ALPHAPHARM

Pty Limited

ACN 002 359 731

Head Office

12 Queen Street

GLEBE NSW 2011

PO Box 36

CAMPERDOWN

NSW 2050

Tel 02 9692 9777

Fax 02 9566 4686

Manufacturing

15 Garnet Street

CAROLE PARK

QLD 4300

Tel 07 3271 3244

Fax 07 3271 5037